Democratic Health Leaders Demand Answers on Trump’s Shady Drug Deals

After another Trump announcement that lacks transparency or any detail, Committee Leaders press major pharmaceutical companies on whether agreements actually lower prices for medications or just enrich Trump's family

WASHINGTON, DC- Ways and Means Committee Ranking Member Richard E. Neal (D-MA), Energy and Commerce Committee Ranking Member Frank Pallone, Jr. (D-NJ), Education and Workforce Committee Ranking Member Robert C. "Bobby" Scott (D-VA), and Senate Finance Committee Ranking Member Ron Wyden (D-OR) demanded transparency from major pharmaceutical companies on their announcements with the Trump Administration on the cost of certain medications, including anti-obesity medications.

Democrats delivered on lower drug prices for the American people by allowing Medicare to negotiate prices, with those savings going into effect in January. These latest announcements from the Trump Administration are just that - announcements. The Administration has yet to provide any public information that the announcements will result in any real savings for consumers. In fact, economists have questioned whether consumers will see any meaningful benefits. The public deserves answers on this and a better understanding of what this means for their everyday costs.

The letters, sent to AstraZeneca, Eli Lilly, Novo Nordisk, and Pfizer, request more information on the contours of the agreements, including the effects on Medicare, future pricing predictions, the parameters of the TrumpRx platform, along with any other benefits the companies are receiving from the Administration as a result of these agreements.

"While President Trump has made misleading and false claims to the American public with rhetoric around lowering drug prices, in reality, actions taken by the Administration thus far have yielded little, and in some cases have raised prices for consumers," the lawmakers wrote. "Skepticism and scrutiny are warranted as the Trump Administration has repeatedly made announcements that fail to meet their stated goals, and instead, only increase costs on the consumer, and yield benefits for the Trump family and Administration."

"Congress and the American people remain in the dark about the contours of [these] agreement[s] with the Trump Administration," the lawmakers continued in their letters to the pharmaceutical companies. "Basic details about the agreement have yet to be confirmed by either [party], making it seem that both parties are attempting to shield themselves from oversight, accountability, and specifics that could inform consumers whether the agreement will save money."

The lawmakers gave the companies until January 5, 2026, to respond.

The letter to AstraZeneca is HERE.

The letter to Eli Lilly is HERE.

The letter to Novo Nordisk is HERE.

The letter to Pfizer is HERE.

###